Anti-MLXPL/ MLXIPL/ CHREBP functional antibody

Anti-MLXPL/ MLXIPL/ CHREBP functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to MLXIPL/MLXIPL products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE1400-Ab-1/ GM-Tg-hg-SE1400-Ab-2Anti-Human MLXIPL monoclonal antibodyHuman
GM-Tg-rg-SE1400-Ab-1/ GM-Tg-rg-SE1400-Ab-2Anti-Rat MLXIPL monoclonal antibodyRat
GM-Tg-mg-SE1400-Ab-1/ GM-Tg-mg-SE1400-Ab-2Anti-Mouse MLXIPL monoclonal antibodyMouse
GM-Tg-cynog-SE1400-Ab-1/ GM-Tg-cynog-SE1400-Ab-2Anti-Cynomolgus/ Rhesus macaque MLXIPL monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE1400-Ab-1/ GM-Tg-felg-SE1400-Ab-2Anti-Feline MLXIPL monoclonal antibodyFeline
GM-Tg-cang-SE1400-Ab-1/ GM-Tg-cang-SE1400-Ab-2Anti-Canine MLXIPL monoclonal antibodyCanine
GM-Tg-bovg-SE1400-Ab-1/ GM-Tg-bovg-SE1400-Ab-2Anti-Bovine MLXIPL monoclonal antibodyBovine
GM-Tg-equg-SE1400-Ab-1/ GM-Tg-equg-SE1400-Ab-2Anti-Equine MLXIPL monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE1400-Ab-1/ GM-Tg-hg-SE1400-Ab-2; GM-Tg-rg-SE1400-Ab-1/ GM-Tg-rg-SE1400-Ab-2;
GM-Tg-mg-SE1400-Ab-1/ GM-Tg-mg-SE1400-Ab-2; GM-Tg-cynog-SE1400-Ab-1/ GM-Tg-cynog-SE1400-Ab-2;
GM-Tg-felg-SE1400-Ab-1/ GM-Tg-felg-SE1400-Ab-2; GM-Tg-cang-SE1400-Ab-1/ GM-Tg-cang-SE1400-Ab-2;
GM-Tg-bovg-SE1400-Ab-1/ GM-Tg-bovg-SE1400-Ab-2; GM-Tg-equg-SE1400-Ab-1/ GM-Tg-equg-SE1400-Ab-2
Products NameAnti-MLXIPL monoclonal antibody
Formatmab
Target NameMLXIPL
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-MLXIPL benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE1400-Ag-1Recombinant multi-species MLXPL/ MLXIPL/ CHREBP protein


    Target information

    Target IDGM-SE1400
    Target NameMLXIPL
    Gene ID51085,58805,171078,720093,489807,101096372,788534,100059888
    Gene Symbol and SynonymsbHLHd14,CHREBP,MIO,MLX,MLXIPL,MONDOB,WBSCR14,WS-bHLH
    Uniprot AccessionQ9NP71,Q8VIP2
    Uniprot Entry NameMLXPL_HUMAN,MLXPL_RAT
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000009950
    Target ClassificationN/A

    The target: MLXIPL, gene name: MLXIPL, also named as CHREBP, MIO, MLX, MONDOB, WBSCR14, WS-bHLH, bHLHd14. This gene encodes a basic helix-loop-helix leucine zipper transcription factor of the Myc/Max/Mad superfamily. This protein forms a heterodimeric complex and binds and activates, in a glucose-dependent manner, carbohydrate response element (ChoRE) motifs in the promoters of triglyceride synthesis genes. The gene is deleted in Williams-Beuren syndrome, a multisystem developmental disorder caused by the deletion of contiguous genes at chromosome 7q11.23. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2015].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.